Ukrainian Laboratories

Synthesis of Styryl-phenyl-ureas as Dual-targeted Inhibitors of PD-L1 and VEGFR-2

Posted by Ukrainian LaboratoriesResponsive · Innovative Products and Technologies · Ukraine

Summary of the technology

We offer the chemical optimization service - synthesis of targets-specific set of styryl-phenyl-urea derivatives as dual-targeted inhibitors of PD-L1 and VEGFR-2.

Ukrainian Laboratories

Description of the technology

Programmed death-ligand 1 (PD-L1, cluster of differentiation 274, CD274, B7 homolog 1 or B7-H1) is a transmembrane protein that plays a major role in suppressing the adaptive arm of immune system during particular events such as tissue allografts, pregnancy, autoimmune disease and some other pathological disease states. Upregulation of PD-L1 may allow cancers to evade the host immune system.

Vascular endothelial growth factor receptor 2 (VEGFR-2, Kinase insert domain receptor, KDR, CD309, FLK1) is a VEGF receptor that plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Abnormal functioning of VEGFR-2 is associated with cancer.

We offer the chemical optimization service - synthesis of targets-specific set of styryl-phenyl-urea derivatives as dual-targeted inhibitors of PD-L1 and VEGFR-2. These novel compounds will be selected from a set of 3,000+ virtual styryl-phenyl-ureas using our company’s proprietary molecular modeling platform, synthesized and provided for your biological projects.

This set of novel analogs will be synthesized exclusively upon your request.

This is referred to a paper from European Journal of Medicinal Chemistry* which showed that authors designed and evaluated styryl-phenyl-ureas as dual-targeted inhibitors of PD-L1 and VEGFR-2 in order to overcome resistance phenomena offered by cancer.

Technology Owner

Ukrainian Laboratories

Research & Technology Organization

Related keywords

  • Biological Sciences
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Industrial Biotechnology
  • Medical Health related
  • Other Medical/Health Related
  • Pharmaceuticals/fine chemicals

About Ukrainian Laboratories

Research & Technology Organization from Ukraine

Otava Institute is a global provider of one-stop integrated research solutions for business and life science. Our team includes chemists, biologists, physicists whose combined efforts contribute to the complex contract research projects for pharmaceutical, agro, cosmetic and material science industries.We are dedicated to providing clients with outstanding service in these key areas and will continue to push boundaries to remain an industry front-runner. Each day we expand our core competencies delivering of new technologies to meet all the customer’s needs.

Our location in Toronto Ontario, Canada provides our clients with the added advantage of North American IP rules and regulations and secure communication and logistics. Our Ukraine – based R&D facilities represented with the Ukrainian Laboratories, that is cooperating with leading Ukrainian research institutions and carries out research work in the format of outsourcing.

We work as a preferred partner to many of the world’s top 10 pharma firms, and hundreds of other companies, providing support with creative solutions for complex technical compound issues. Our scientific knowledge, combined with our research and manufacturing capability, enables us to support chemical processing and production without ever compromising on quality.

Our experience, dedication, and commitment to quality make us an ideal partner for discovery stage research.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.